Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC)

Biomarkers

Volumn 19, Issue 3, 2014, Pages 198-206

  Nagalakshmi, K ^a,b   Jamil, Kaiser ^a   Pingali, Usharani ^b   Reddy, M Vishnuvardhan ^c   Attili, Suresh S V ^d  

^a Bhagwan Mahavir Medical Research Centre   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^c Govt ENT Hospital   (India)

^d Bibi Cancer Hospital and Research Institute   (India)

Author keywords

Biomarkers; EGFR; Head and neck squamous cell carcinoma; Receptor signalling; Risk factors; Single nucleotide polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PRIMER DNA;

ADULT; ADVANCED CANCER; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GROUPS BY AGE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFIRMATORY POLYMORPHISM; SMOKING; EXON; GENETICS; HEAD AND NECK TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; SQUAMOUS CELL CARCINOMA;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; EXONS; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899723869     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.895852     Document Type: Article

References (50)

1. Agrawal N, Frederick MJ, Pickering CR, et al. (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 6046:1154-7.
2. Araújo A, Ribeiro R, Azevedo I, et al. (2007). Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer. Oncologist 2:201-10.
3. Basu R, Mandal S, Ghosh A, Poddar TK. (2008). Role of tobacco in the development of head and neck squamous cell carcinoma in an eastern Indian population. Asian Pac J Cancer Prev 9:381-6.
4. Chiu TJ, Chen YJ, Rau KM, et al. (2013). Midkine neurite growthpromoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma. Biomarkers 18:687-98.
5. Chung CH, Ely K, McGavran L, et al. (2006). Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170-6.
6. Ciardiello F, Tortora G. (2003). Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348-54.
7. Cohen EE, Rosen F, Stadler WM, et al. (2003). Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-7.
8. Cortesina G, Martone T. (2006). Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature. Acta Otorhinolaryngol Ital 26:317-25.
9. Denaro N, Lo Nigro C, Natoli G, et al. (2011). The role of p53 and MDM2 in head and neck cancer. ISRN Otolaryngology 2011:article ID 931813, 8 pages.
10. Dibb NJ, Dilworth SM, Mol CD. (2004). Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev 4: 718-27.
11. Elahi M, Rakhshan V, Ghasemian NT, Moshref M. (2012). Prognostic value of transforming growth factor beta 1 [TGF-b1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers 17:21-7.
12. Farnebo L, Jedlinski A, Ansell A, et al. (2009). Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predic t cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med 4:549-56.
13. Greulich H, Chen TH, Feng W, et al. (2005). Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2:313.
14. Hama T, Yuza Y, Saito Y, et al. (2009). Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14:900-8.
15. Hang L, Yunjian P, Yuan L, et al. (2013). Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 79:8-13 .
16. Harari PM, Allen GW, Bonner JA. (2007). Biology of interactions: anti epidermal growth factor receptor agents. J Clin Oncol 25:4057-65.
17. Hsieh YY, Tzeng CH, Chen MH, et al. (2012). Epidermal growth factor receptor R521K polymorphism shows favorable outcome to cetuximab-based treatment in KRAS wild-type colorectal cancer patients. Cancer Sci 4:791-6.
18. Jorissen RN, Walker F, Pouliot N, et al. (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53.
19. Kaneko K, Kumekawa Y, Makino R, et al. (2010). EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 15:65-72.
20. Krohn V, Wiegand S, Werner JA, Mandic R. (2011). EGFR codon 497 polymorphism-implications for receptor sensitivity to inhibitors in HNSCC cell lines. Anticancer Res 1:59-65.
21. Lee JW, Soung YH, Kim SY, et al. (2005). Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879-82.
22. Lemos-Gonzalez Y, Paez de la Cadena M, Rodriguez-Berrocal FJ, et al. (2007). Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biol 2 8:273-9.
23. Linardou H, Dahabreh IJ, Bafaloukos D, et al. (2009). Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Rev Clin Oncol 6:352-66.
24. Lo HW, Hsu SC, Hung MC. (2006). EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 3:211-18.
25. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al. (2006). Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carinoma. Eur J Cancer 42: 109-11.
26. Lynch TJ, Bell DW, Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-39.
27. Mellon K, Wright C, Kelly P, et al. (1995). Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 2: 919-25.
28. Miller SA, Dykes DD, Polesky HF.1988). A simple salting-out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 16:1215.
29. Na II, Kan HJ, Cho SY, et al. (2007). EGFR mutations and human papillomavirus is squamous cell carcinoma of tongue and tonsil. Eur J Cancer 43:520-6.
30. Nagalakshmi K, Jamil K, Usharani P. (2013). Association of EGFR gene polymorphisms in head and neck cancer patients with tobacco and alcohol consuming habits. Biol Med 5:69-77.
31. Nomura M, Shigematsu H, Li L, et al. (2007). Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4:125.
32. Paez JG, Janne PA, Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinicalresponse to gefitinib therapy. Science 304:1497-500.
33. Pao W, Miller V, Zakowski M, et al. (2004). EGF receptor gene mutations are common in lung cancers fromnever smokersand are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-11.
34. Rong R, Tull J, Zhang S. (2012). Molecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma. J Solid Tumors 2:27-31.
35. Sabitha K Kaiser J. 2006, Analysis of EGFR gene mutations which have a response to quinazolin inhibitors, Comparative Evol Genom Proteom, 5, 229-32..
36. Sabitha K, Reddy MVV, Kaiser J. (2008). GST genotypes in head and neck cancer patients and its clinical implications. Afr J Biotechnol 7: 3853-9.
37. Sabitha K, Reddy MVV, Kaiser J. (2010). Smoking related risk involved in individuals carrying genetic variants of CYP1A1 gene in head and neck cancer. Cancer Epidemiol 34:5587-92.
38. Sahoo R, Harini VV, Babu VC, et al. (2011). Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73: 316-19.
39. Sharma SV, Bell DW, Settleman J, Haber DA. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-81.
40. Shigematsu H, Lin L, Takahashi T, et al. (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-46.
41. Sordella R, Bell DW, Haber DA, Settleman J. (2004). Gefitinibsensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-7.
42. Stransky N, Egloff AM, Tward AD,et al. (2011). The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-60.
43. Takano T, Ohe Y, Sakamoto H, et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829-37.
44. Tanner M, Hollmen M, Junttila TT, et al. (2005). Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2:273-8.
45. Temam S, Kawaguchi H, El-Naggar AK, et al. (2007). Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164-70.
46. Tokumo M, Toyooka S, Kiura K, et al. (2005). The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-73.
47. Willmore-Payne C, Holden JA,Layfield LJ. (2006). Detection of EGFRand HER2-activating mutations in squamous cell carcinoma involving the head and neck. Modern Pathol 19:634-40.
48. Wu JY,Wu SG, Yang CH, et al. (2008). Lung cancer with EGFR exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14:4877-82.
49. Yen C-Y, Huang C-Y, Hou M-F, et al. (2013). Evaluating the performance of fibronectin 1 (FN1), integrin a4b1 (ITGA4), syndecan-2 (SDC2), and glycoprotein CD44 as the potential biomarkers of oral squamous cell carcinoma (OSCC). Biomarkers 18: 63-72.
50. Yoshikawa S, Kukimoto-Niino M, Parker L, et al. (2013). Structural basis for the altered drug sensitivities of non-small cell lung cancerassociated mutants of human epidermal growth factor receptor. Oncogene 32:27-38.